Table 4.
Risk Factors for Death of Critically Ill Patients with COVID-19 Pneumonia
Variable | P-value | Crude HR | 95% CI | P-value | Adjusted HR | 95% CI |
---|---|---|---|---|---|---|
Age >70 years | 0.0019 | 2.757 | 1.453–5.231 | 0.0299 | 3.323 | 1.124–9.823 |
Fatigue | 0.0019 | 2.727 | 1.447–5.137 | 0.5184 | 1.376 | 0.522–3.630 |
Diarrhea | 0.3430 | 1.346 | 0.728–2.489 | |||
Smoking history | 0.2368 | 1.568 | 0.744–3.306 | |||
Lymphocyte count, ×109/L | 0.0265 | 0.160 | 0.032–0.808 | 0.5534 | 0.436 | 0.028–6.780 |
Platelet count, ×109/L | 0.0488 | 0.995 | 0.991–1.000 | 0.4098 | 0.997 | 0.991–1.004 |
D-dimer, μg/mL | 0.0759 | 1.030 | 0.997–1.065 | |||
FDP, μg/mL | 0.0523 | 1.005 | 1.000–1.01 | |||
Total T cell, n/μL | 0.0985 | 0.997 | 0.993–1.001 | |||
CD4+ T cell, n/μL | 0.1459 | 0.996 | 0.991–1.001 | |||
Interleukin 8, pg/mL | 0.0001 | 1.007 | 1.004–1.011 | 0.1261 | 1.005 | 0.999–1.012 |
Non-invasive MV | 0.0455 | 2.429 | 1.018–5.798 | 0.9071 | 0.913 | 0.197–4.236 |
Invasive MV | 0.0006 | 4.230 | 1.856–9.638 | 0.1991 | 0.355 | 0.073–1.725 |
Vasoconstrictive agents | 0.0002 | 5.966 | 2.317–15.366 | 0.3686 | 2.209 | 0.392–12.434 |
IFN α-2b | 0.0019 | 0.194 | 0.069–0.546 | 0.0850 | 0.263 | 0.058–1.202 |
ARDS | 0.0932 | 2.017 | 0.889–4.576 | |||
AKI | 0.0001 | 3.512 | 1.839–6.708 | 0.2385 | 1.883 | 0.657–5.394 |
Cardiac injury | 0.0012 | 3.498 | 1.640–7.462 | 0.9237 | 0.943 | 0.286–3.107 |
Arrhythmia | 0.0002 | 3.452 | 1.790–6.655 | 0.0053 | 4.760 | 1.590–14.252 |
Liver dysfunction | 0.1284 | 1.693 | 0.859–3.336 | |||
APACHE IIs>15 | 0.0013 | 2.859 | 1.508–5.419 | 0.1731 | 0.493 | 0.178–1.364 |
SOFA score>4 | 0.0007 | 3.533 | 1.704–7.324 | 0.0201 | 5.156 | 1.294–20.548 |
Ratio of PaO2 to FiO2 | 0.0279 | 0.997 | 0.993–1.000 | 0.5094 | 0.998 | 0.992–1.004 |
Abbreviations: HR, hazard ratio; CI, confidence interval; FDP, fibrinogen degradation product; MV, mechanical ventilation; IFN, interferon; ARDS, acute respiratory distress syndrome; AKI, acute kidney injury; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ Failure Assessment.